导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.58% | 4030/4773 |
| 近一周 | -2.69% | 4157/5465 |
| 近一月 | -1.05% | 1007/5421 |
| 近一季 | -1.36% | 1201/5231 |
| 近半年 | -5.57% | 3057/4920 |
| 近一年 | -12.14% | 3526/4394 |
| 近两年 | 31.33% | 2227/2954 |
| 近三年 | 16.20% | 1609/2253 |
| 成立以来 | 9.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.76% 4679/4961 |
3.57% 2939/5312 |
- - |
- - |
| 2025 | 10.07% 2833/4813 |
-5.83% 3318/3635 |
6.13% 488/4076 |
7.97% 3425/4524 |
2.00% 1114/4813 |
| 2024 | 32.88% 81/3463 |
-3.32% 1488/2808 |
-4.44% 1507/3014 |
43.37% 11/3129 |
0.32% 1231/3463 |
| 2023 | 0.92% 385/2656 |
2.46% 1345/2280 |
-0.70% 406/2385 |
6.72% 67/2515 |
-7.05% 2029/2655 |
| 2022 | -19.46% 853/2207 |
-15.51% 1043/1919 |
2.16% 1339/2016 |
-13.91% 994/2113 |
8.39% 265/2208 |
| 2021 | -10.95% 1101/1822 |
-13.10% 1152/1255 |
1.28% 1061/1330 |
-0.65% 499/1466 |
1.83% 788/1822 |
| 2020 | 17.84% 756/1250 |
-12.17% 874/1028 |
8.29% 826/1067 |
20.34% 57/1164 |
2.96% 951/1184 |
| 2019 | 48.79% 110/1092 |
41.56% 37/739 |
-1.91% 329/788 |
-1.16% 634/850 |
8.42% 319/918 |
| 2018 | -23.54% 287/834 |
- - |
-12.58% 399/631 |
2.87% 93/660 |
-6.72% 51/682 |
| 2017 | 12.48% 274/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.16% 319/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证证券保险A VS. 长安沪深300非周期A(740101) |